|
Metaproterenol
resources
|
|
|
|
|
|
DRUG INFO
Metaproterenol
Drug Name:
Metaproterenol
Indication: For the treatment of Bronchospasm; Chronic bronchitis; Asthma; Emphysema
Pharmacology: Metaproterenol, a synthetic amine, is structurally and pharmacologically similar to isoproterenol. Metaproterenol is used exclusively as a bronchodilator. The pharmacologic effects of beta adrenergic agonist drugs, such as Metaproterenol, are at least in part attributable to stimulation through beta adrenergic receptors of intracellular adenyl cyclase, the enzyme which catalyzes the conversion of adenosine triphosphate (ATP) to cyclic- 3',5'- adenosine monophosphate (c-AMP). Increased c-AMP levels are associated with relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells.
Mechanism Of Action: Metaproterenol is a moderately selective beta(2)-adrenergic agonist that stimulates receptors of the smooth muscle in the lungs, uterus, and vasculature supplying skeletal muscle, with minimal or no effect on alpha-adrenergic receptors. Intracellularly, the actions of metaproterenol are mediated by cAMP, the production of which is augmented by beta stimulation. The drug is believed to work by activating adenylate cyclase, the enzyme responsible for producing the cellular mediator cAMP.
Drug Category: Tocolytic Agents; Bronchodilator Agents; ATC:R03AC
Brand Names/Synonyms: Alotec; Alupent; CHEMBANK1252; Metaprel; Metaproterenol; Metaproterenol Polistirex; Metaproterenol Polistirex [Usan]; Metaproterenol Sulfate; Novasmasol; ORCIPRENALINE; Orciprenalina [Inn-Spanish]; Orciprenalinum [Inn-Latin]; Prometa
Dosage Forms: Inhalation
Absorption: 3% (oral bioavailability of 40%)
Interactions:
DrugBank: Interactions for Metaproterenol
Interactions for Metaproterenol:
Other beta adrenergic aerosol bronchodilators should not be used concomitantly with
Alupent® (metaproterenol sulfate USP) because they may have additive effects. Beta adrenergic agonists
should be administered with caution to patients being treated with monoamine oxidase inhibitors or tricyclic
antidepressants, since the action of beta adrenergic agonists on the vascular system may be potentiated.
Chemical IUPAC Name: 5-[1-hydroxy-2-(1-methylethylamino)ethyl]benzene-1,3-diol
Chemical Formula: C11H17NO3
Half Life: 6 hours
Drug Type: Approved Drug
# Accession No: APRD00210
CAS Registry Number: 586-06-1
|
|
|
|
|
|
Metaproterenol News
(When available)
Hythiam Announces AAR Counseling Services to License PROMETA(TM) ... Jan 12, 2006
Business Wire (press release), LOS ANGELES--(BUSINESS WIRE)--Jan. 12, 2006--Hythiam, Inc. (NASDAQ:HYTM), a healthcare services management company that licenses the PROMETA(TM) physiological ...
Hythiam CEO Terren Peizer to Speak at National Association of ... Jan 10, 2006
Genetic Engineering News, Hythiam, Inc. (NASDAQ:HYTM), a healthcare services management company that licenses the PROMETA(TM) physiological protocols designed to treat substance ...
Helping friends, family stay sober Dec 23, 2005
El Dorado Times, Called Prometa(tm), the treatments are designed to address the neurochemical imbalances in the brain that are caused by chronic substance abuse, and which are ...
|
|
|
